
ALLK
NGSAllakos Inc.
Healthcare•Biotechnology
Watchlists:
Last updated: Thursday 15th May 2025
0.33
0.00 (-0.06%)
Prev Close:0.3293
Open:0.3283
Bid:0.3285
Ask:0.33
52 Week Range
0.221.56
Volume:1,215,891
Mkt Cap:30 M
47
MarketXLS Rank ®
Hold
Price Target
$0.38
+15.5%
Financial Statements
ALLK - Income Statement (Annual)
Dec-24 | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Invalid date | |
---|---|---|---|---|---|---|---|---|
Basic EPS From Continuing Operations | -1.3 | -2.14 | -5.06 | -5.01 | -3.1 | -1.89 | ||
Basic EPS Total | -1.3 | -2.14 | -5.06 | -5.01 | -3.1 | -1.89 | ||
Basic Weighted Shares Outstanding | 89 M | 87 M | 63 M | 54 M | 49 M | 45 M | 20 M | |
Depreciation | 8 M | 6 M | 7 M | 2 M | 2 M | 2 M | -200000.0 | |
Depreciation And Amortization | 8 M | 6 M | 7 M | 2 M | 2 M | 2 M | -200000.0 | |
Diluted EPS Total | -1.3 | -2.14 | -5.06 | -5.01 | -3.1 | -1.89 | -2.2 | |
Diluted Normalized Net Income/share | -1.3 | -2.14 | -5.06 | |||||
Diluted Weighted Shares Outstanding | 89 M | 87 M | 63 M | 49 M | 45 M | 20 M | ||
Gain On Sale Of PPE | 24 M | |||||||
General And Administrative Expense | 39 M | 45 M | 57 M | 75 M | 52 M | 30 M | 12 M | |
Income Before Tax | -116 M | -186 M | -320 M | -270 M | -153 M | -85 M | -44 M | |
Interest Income | 6 M | 10 M | 4 M | 377000.0 | 4 M | 6 M | 2 M | |
Misc Other Special Charges | -43000.0 | 8000.0 | -1 M | 1 M | -736000.0 | -155000.0 | -192000.0 | |
Net Income From Total Operations | -116 M | -186 M | -320 M | -270 M | -153 M | -85 M | -44 M | |
Net Income Common Stockholders | -116 M | -186 M | -320 M | -270 M | -153 M | -85 M | -44 M | |
Net Income Continuous Operations | -116 M | -186 M | -320 M | -270 M | -153 M | -85 M | -44 M | |
Net Non Operating Interest Income Expense | 6 M | 10 M | 4 M | 377000.0 | 4 M | 6 M | 2 M | |
Normalized Income | -111 M | |||||||
Operating Income | -122 M | -196 M | -322 M | -271 M | -157 M | -91 M | -46 M | |
Operating Income Before Depreciation (EBITDA) | -108 M | -180 M | -315 M | -269 M | -156 M | -87 M | -45 M | |
Operating Expense | 122 M | 196 M | 322 M | 271 M | 157 M | 91 M | -46 M | |
Other Income Net | 3 M | -8000.0 | -1 M | -1 M | 736000.0 | 155000.0 | 192000.0 | |
Other Gand A | 39 M | 45 M | 57 M | 75 M | 52 M | 30 M | 12 M | |
Other Impairment Of Capital Assets | 27 M | |||||||
Other Operating Expenses | -969000.0 | -2 M | -2 M | -5 M | -3 M | -2 M | -678000.0 | |
Rent And Landing Fees | 12 M | |||||||
Research & Development Expense | 80 M | 151 M | 265 M | 196 M | 106 M | 62 M | 33 M | |
Research Expense | 80 M | 151 M | 265 M | 196 M | 106 M | 62 M | 33 M | |
Salaries And Wages | -5 M | |||||||
Selling Gen & Administrative Expense | 39 M | 45 M | 57 M | 75 M | 52 M | 30 M | 12 M | |
Total Income Available For Interest Expense (EBIT) | -116 M | -186 M | -322 M | -271 M | -157 M | -85 M | -44 M | |
Total Common Shares Outstanding | 90 M | 88 M | 86 M | 55 M | 53 M | 49 M | 43 M | |
Total Net Income | -116 M | -186 M | -320 M | -270 M | -153 M | -85 M | -44 M | |
Total Ordinary Shares | 90 M | 90 M | 90 M | 90 M | 90 M | 90 M | 90 M | |
Total Expenses | 122 M | 196 M | 322 M | 271 M | 157 M | 91 M | -46 M |